Comparison of Efficacy and Specificity in Cancer-Targeting Prodrug Conjugates
May 2022
in “
The FASEB journal
”
Studysummary This article discusses the development of targeted prodrug conjugates aimed at selectively attacking cancer cells while avoiding healthy ones, but reports no experimental results yet.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on faseb.onlinelibrary.wiley.com →